{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:41:02Z","timestamp":1740148862081,"version":"3.37.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["AGL2010-16678"],"award-info":[{"award-number":["AGL2010-16678"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["AGL2014-56427-P"],"award-info":[{"award-number":["AGL2014-56427-P"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Leishmaniases are a group of neglected tropical parasitic diseases, mainly affecting vulnerable populations of countries with poor socioeconomic status. Development of efficient vaccines is a priority due to the increasing incidence of drug resistance and toxicity to current treatments. In the search for a safe and efficient protective vaccine for human and dog visceral leishmaniases, we analyzed the suitability of the immunomodulatory drug sirolimus (SIR) to boost a preventive DNA vaccine against leishmaniasis. SIR is an already marketed drug that has been described to boost immune protection against different disease models and has also emerged as a promising therapeutic drug against<jats:italic>L. major<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Syrian hamsters were treated with SIR concomitantly with the administration of a DNA vaccine formulation consisting in four plasmids carrying the<jats:italic>Leishmania<\/jats:italic>genes<jats:italic>LACK<\/jats:italic>,<jats:italic>TRYP<\/jats:italic>,<jats:italic>PAPLE22<\/jats:italic>and<jats:italic>KMPII<\/jats:italic>, respectively. Two weeks after the last vaccination, the animals were infected intraperitoneally with<jats:italic>L. infantum<\/jats:italic>parasites. Five weeks post-infection the parasite load was measured by real-time PCR in target tissues and immune response was evaluated by determining anti-<jats:italic>Leishmania<\/jats:italic>specific antibodies in combination with cytokine expression in the spleen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our results show that the DNA vaccine itself efficiently reduced the burden of parasites in the skin (<jats:italic>P<\/jats:italic>= 0.0004) and lymph nodes (<jats:italic>P<\/jats:italic>= 0.0452). SIR administration also enhanced the protection by reducing the parasite load in the spleen (<jats:italic>P<\/jats:italic>= 0.0004). Vaccinated animals with or without SIR co-treatment showed lower IFN-\u03b3 expression levels than those found in the spleen of control animals. mRNA expression levels of NOS2 and IL-10 were found to be significantly higher in the vaccinated plus SIR treated group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Co-administration of SIR enhances a DNA vaccination regimen against<jats:italic>L. infantum<\/jats:italic>, improving the reduction of parasite load in skin, lymph node and spleen. The analysis of immune markers in the spleen after challenge suggests that the trend to recover na\u00efve levels of IFN-\u03b3 and IL-10, and the concurrent higher expression of NOS2, may be responsible for the protection induced by our vaccine co-administered with SIR.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13071-020-04165-4","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T08:02:39Z","timestamp":1591689759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sirolimus enhances the protection achieved by a DNA vaccine against Leishmania infantum"],"prefix":"10.1186","volume":"13","author":[{"given":"Alba","family":"Mart\u00ednez-Fl\u00f3rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Martori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula L.","family":"Monteagudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Alberola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3617-0119","authenticated-orcid":false,"given":"Alhel\u00ed","family":"Rodr\u00edguez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"4165_CR1","doi-asserted-by":"publisher","first-page":"e02851","DOI":"10.7554\/eLife.02851","volume":"3","author":"DM Pigott","year":"2014","unstructured":"Pigott DM, Bhatt S, Golding N, Duda KA, Battle KE, Brady OJ, et al. Global distribution maps of the leishmaniases. Elife. 2014;3:e02851.","journal-title":"Elife."},{"key":"4165_CR2","first-page":"873","volume":"5","author":"F Chappuis","year":"2007","unstructured":"Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Immunol. 2007;5:873\u201382.","journal-title":"Nat Rev Immunol."},{"key":"4165_CR3","volume-title":"Sustaining the drive to overcome the global impact of neglected tropical diseases","author":"WHO","year":"2013","unstructured":"WHO. Sustaining the drive to overcome the global impact of neglected tropical diseases. Geneva: World Health Organization; 2013."},{"key":"4165_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/sj.icb7100011","volume":"85","author":"AC Stanley","year":"2007","unstructured":"Stanley AC, Engwerda CR. Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol. 2007;85:138\u201347.","journal-title":"Immunol Cell Biol."},{"key":"4165_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.0105-2896.2004.00188.x","volume":"201","author":"PM Kaye","year":"2004","unstructured":"Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, et al. The immunopathology of experimental visceral leishmaniasis. Immunol Rev. 2004;201:239\u201353.","journal-title":"Immunol Rev."},{"key":"4165_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.0141-9838.2004.00672.x","volume":"25","author":"P Tsagozis","year":"2003","unstructured":"Tsagozis P, Karagouni E, Dotsika E. CD8+ T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol. 2003;25:569\u201379.","journal-title":"Parasite Immunol."},{"key":"4165_CR7","doi-asserted-by":"publisher","first-page":"e2914","DOI":"10.1371\/journal.pntd.0002914","volume":"8","author":"RJ Faleiro","year":"2014","unstructured":"Faleiro RJ, Kumar R, Hafner LM, Engwerda CR. Immune regulation during chronic visceral leishmaniasis. PLoS Negl Trop Dis. 2014;8:e2914.","journal-title":"PLoS Negl Trop Dis."},{"key":"4165_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/infdis\/154.6.1003","volume":"154","author":"R Badaro","year":"1986","unstructured":"Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003\u201311.","journal-title":"J Infect Dis."},{"key":"4165_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1590\/S0074-02762012000600005","volume":"107","author":"ASA Costa","year":"2012","unstructured":"Costa ASA, Costa GC, de Aquino DMC, de Mendon\u00e7a VRR, Barral A, Barral-Netto M, et al. Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis. Mem Inst Oswaldo Cruz. 2012;107:735\u20139.","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"4165_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1017\/S0031182016002031","volume":"145","author":"S Hendrickx","year":"2018","unstructured":"Hendrickx S, Guerin P, Caljon G, Croft S, Maes L. Evaluating drug resistance in visceral leishmaniasis: the challenges. Parasitology. 2018;145:453\u201363.","journal-title":"Parasitology."},{"key":"4165_CR11","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/cid\/cit102","volume":"56","author":"S Rijal","year":"2013","unstructured":"Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TPC, et al. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis. 2013;56:1530\u20138.","journal-title":"Clin Infect Dis."},{"key":"4165_CR12","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1016\/j.vaccine.2009.07.069","volume":"27","author":"J Carcel\u00e9n","year":"2009","unstructured":"Carcel\u00e9n J, Iniesta V, Fern\u00e1ndez-Cotrina J, Serrano F, Parejo JC, Corraliza I, et al. The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection. Vaccine. 2009;27:5964\u201373.","journal-title":"Vaccine."},{"key":"4165_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.mib.2012.05.002","volume":"15","author":"AP Fernandes","year":"2012","unstructured":"Fernandes AP, Coelho EAF, Machado-Coelho GLL, Grimaldi G, Gazzinelli RT. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Curr Opin Microbiol. 2012;15:476\u201385.","journal-title":"Curr Opin Microbiol."},{"key":"4165_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.vetpar.2013.05.008","volume":"197","author":"G Bongiorno","year":"2013","unstructured":"Bongiorno G, Paparcone R, Manzillo VF, Oliva G, Cuisinier AM, Gradoni L. Vaccination with LiESP\/QA-21 (CaniLeish) reduces the intensity of infection in Phlebotomus perniciosus fed on Leishmania infantum infected dogs\u2014a preliminary xenodiagnosis study. Vet Parasitol. 2013;197:691\u20135.","journal-title":"Vet Parasitol."},{"key":"4165_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13071-016-1553-y","volume":"9","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Shankar P, Mishra J, Singh S. Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasit Vectors. 2016;9:277.","journal-title":"Parasit Vectors."},{"key":"4165_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0952-7915(00)00118-7","volume":"12","author":"S Gurunathan","year":"2000","unstructured":"Gurunathan S, Wu CY, Freidag BL, Seder RA. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol. 2000;12:442\u20137.","journal-title":"Curr Opin Immunol."},{"key":"4165_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","volume":"18","author":"S Gurunathan","year":"2000","unstructured":"Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000;18:927\u201374.","journal-title":"Annu Rev Immunol."},{"key":"4165_CR18","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1016\/j.vaccine.2007.08.023","volume":"25","author":"A Rodr\u00edguez-Cort\u00e9s","year":"2007","unstructured":"Rodr\u00edguez-Cort\u00e9s A, Ojeda A, L\u00f3pez-Fuertes L, Tim\u00f3n M, Altet L, Solano-Gallego L, et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine. 2007;25:7962\u201371.","journal-title":"Vaccine."},{"key":"4165_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/S003118201600216X","volume":"145","author":"Y Taslimi","year":"2018","unstructured":"Taslimi Y, Zahedifard F, Rafati S. Leishmaniasis and various immunotherapeutic approaches. Parasitology. 2018;145:497\u2013507.","journal-title":"Parasitology."},{"key":"4165_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fimmu.2012.00144","volume":"3","author":"VS Raman","year":"2012","unstructured":"Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG. Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol. 2012;3:144.","journal-title":"Front Immunol."},{"key":"4165_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","volume":"59","author":"RN Saunders","year":"2001","unstructured":"Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59:3\u201316.","journal-title":"Kidney Int."},{"key":"4165_CR22","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.4049\/jimmunol.178.11.7018","volume":"178","author":"HR Turnquist","year":"2007","unstructured":"Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178:7018\u201331.","journal-title":"J Immunol."},{"key":"4165_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"DM Sabatini","year":"2012","unstructured":"Sabatini DM, Laplante M. MTOR signaling in growth control and disease. Cell. 2012;149:274\u201393.","journal-title":"Cell."},{"key":"4165_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08155","volume":"460","author":"K Araki","year":"2009","unstructured":"Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. MTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460:108\u201312.","journal-title":"Nature."},{"key":"4165_CR25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ni.2741","volume":"14","author":"R Keating","year":"2013","unstructured":"Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol. 2013;14:1266\u201376.","journal-title":"Nat Immunol."},{"key":"4165_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1600-6143.2010.03407.x","volume":"11","author":"AP Turner","year":"2011","unstructured":"Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in Rhesus macaques. Am J Transplant. 2011;11:613\u20138.","journal-title":"Am J Transplant."},{"key":"4165_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1158\/2326-6066.CIR-13-0046","volume":"1","author":"M Diken","year":"2013","unstructured":"Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, et al. MTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol Res. 2013;1:386\u201392.","journal-title":"Cancer Immunol Res."},{"key":"4165_CR28","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.4049\/jimmunol.1103365","volume":"188","author":"Q Li","year":"2012","unstructured":"Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, et al. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol. 2012;188:3080\u20137.","journal-title":"J Immunol."},{"key":"4165_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-1-61779-430-8_18","volume":"821","author":"C Jagannath","year":"2012","unstructured":"Jagannath C, Bakhru P. Rapamycin-induced enhancement of vaccine efficacy in mice. Methods Mol Biol. 2012;821:295\u2013303.","journal-title":"Methods Mol Biol."},{"key":"4165_CR30","doi-asserted-by":"publisher","first-page":"e0006701","DOI":"10.1371\/journal.pntd.0006701","volume":"12","author":"F Khadir","year":"2018","unstructured":"Khadir F, Shaler CR, Oryan A, Rudak PT, Mazzuca DM, Taheri T, et al. Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin. PLoS Negl Trop Dis. 2018;12:e0006701.","journal-title":"PLoS Negl Trop Dis."},{"key":"4165_CR31","doi-asserted-by":"publisher","first-page":"e51181","DOI":"10.1371\/journal.pone.0051181","volume":"7","author":"F Todol\u00ed","year":"2012","unstructured":"Todol\u00ed F, Rodr\u00edguez-Cort\u00e9s A, del Carmen N\u00fa\u00f1ez M, Laurenti MD, G\u00f3mez-Sebasti\u00e1n S, Rodr\u00edguez F, et al. Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania. PLoS ONE. 2012;7:e51181.","journal-title":"PLoS ONE."},{"key":"4165_CR32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1645\/GE-2566.1","volume":"96","author":"SM Lei","year":"2010","unstructured":"Lei SM, Romine NM, Beetham JK. Population changes in Leishmania chagasi promastigote developmental stages due to serial passage. J Parasitol. 2010;96:1134\u20138.","journal-title":"J Parasitol."},{"key":"4165_CR33","doi-asserted-by":"publisher","first-page":"e0003490","DOI":"10.1371\/journal.pntd.0003490","volume":"9","author":"L Pereira","year":"2015","unstructured":"Pereira L, Abbehusen M, Teixeira C, Cunha J, Nascimento IP, Fukutani K, et al. Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters. PLoS Negl Trop Dis. 2015;9:e0003490.","journal-title":"PLoS Negl Trop Dis."},{"key":"4165_CR34","doi-asserted-by":"publisher","first-page":"e0004322","DOI":"10.1371\/journal.pntd.0004322","volume":"10","author":"JA Fiuza","year":"2016","unstructured":"Fiuza JA, Dey R, Davenport D, Abdeladhim M, Meneses C, Oliveira F, et al. Intradermal immunization of Leishmania donovani centrin knock-out parasites in combination with salivary protein LJM19 from sand fly vector induces a durable protective immune response in hamsters. PLoS Negl Trop Dis. 2016;10:e0004322.","journal-title":"PLoS Negl Trop Dis."},{"key":"4165_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.vetpar.2006.01.011","volume":"137","author":"O Francino","year":"2006","unstructured":"Francino O, Altet L, S\u00e1nchez-Robert E, Rodriguez A, Solano-Gallego L, Alberola J, et al. Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol. 2006;137:214\u201321.","journal-title":"Vet Parasitol."},{"key":"4165_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jim.2011.02.004","volume":"368","author":"M Zivcec","year":"2011","unstructured":"Zivcec M, Safronetz D, Haddock E, Feldmann H, Ebihara H. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J Immunol Methods. 2011;368:24\u201335.","journal-title":"J Immunol Methods."},{"key":"4165_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2172-11-31","volume":"11","author":"CM Espitia","year":"2010","unstructured":"Espitia CM, Zhao W, Saldarriaga O, Osorio Y, Harrison LM, Cappello M, et al. Duplex real-time reverse transcriptase PCR to determine cytokine mRNA expression in a hamster model of New World cutaneous leishmaniasis. BMC Immunol. 2010;11:31.","journal-title":"BMC Immunol."},{"key":"4165_CR38","unstructured":"Ensembl. Ensembl genome browser 88. 2017. https:\/\/www.ensembl.org\/index.html. Accessed 17 Jan 2019."},{"key":"4165_CR39","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016. https:\/\/www.R-project.org\/."},{"key":"4165_CR40","doi-asserted-by":"crossref","unstructured":"Mair P, Wilcox R. WRS2: a collection of robust statistical methods. 2015. https:\/\/cran.r-project.org\/package=WRS2. Accessed 25 May 2020.","DOI":"10.32614\/CRAN.package.WRS2"},{"key":"4165_CR41","volume-title":"Introduction to robust estimation and hypothesis testing","author":"RR Wilcox","year":"2012","unstructured":"Wilcox RR. Introduction to robust estimation and hypothesis testing. 3rd ed. Waltham: Academic Press; 2012.","edition":"3"},{"key":"4165_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","volume":"29","author":"T Weichhart","year":"2008","unstructured":"Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29:565\u201377.","journal-title":"Immunity."},{"key":"4165_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imm.12126","volume":"140","author":"A Mercalli","year":"2013","unstructured":"Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, et al. Rapamycin unbalances the polarization of human macrophages to M1. Immunology. 2013;140:179\u201390.","journal-title":"Immunology."},{"key":"4165_CR44","doi-asserted-by":"publisher","first-page":"e12586","DOI":"10.1111\/pim.12586","volume":"40","author":"A Kumar","year":"2018","unstructured":"Kumar A, Das S, Mandal A, Verma S, Abhishek K, Kumar A, et al. Leishmania infection activates host mTOR for its survival by M2 macrophage polarization. Parasite Immunol. 2018;40:e12586.","journal-title":"Parasite Immunol."},{"key":"4165_CR45","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","volume":"174","author":"R Basu","year":"2005","unstructured":"Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol. 2005;174:7160\u201371.","journal-title":"J Immunol."},{"key":"4165_CR46","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.1073\/pnas.0712153105","volume":"105","author":"R Gomes","year":"2008","unstructured":"Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, Silva C, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci USA. 2008;105:7845\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4165_CR47","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.4049\/jimmunol.176.9.5519","volume":"176","author":"LE Perez","year":"2006","unstructured":"Perez LE, Chandrasekar B, Saldarriaga OA, Zhao W, Arteaga LT, Travi BL, et al. Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J Immunol. 2006;176:5519\u201328.","journal-title":"J Immunol."},{"key":"4165_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1668","volume":"5","author":"V Bronte","year":"2005","unstructured":"Bronte V, Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol. 2005;5:641\u201354.","journal-title":"Nat Rev Immunol."},{"key":"4165_CR49","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1172\/JCI77746","volume":"125","author":"KN Pollizzi","year":"2015","unstructured":"Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, et al. MTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. J Clin Investig. 2015;125:2090\u2013108.","journal-title":"J Clin Investig"},{"key":"4165_CR50","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","volume":"166","author":"PC Melby","year":"2001","unstructured":"Melby PC, Chandrasekar B, Zhao W, Coe JE. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol. 2001;166:1912\u201320.","journal-title":"J Immunol."},{"key":"4165_CR51","doi-asserted-by":"publisher","first-page":"e1006165","DOI":"10.1371\/journal.ppat.1006165","volume":"13","author":"F Kong","year":"2017","unstructured":"Kong F, Saldarriaga OA, Spratt H, Osorio EY, Travi BL, Luxon BA, et al. Transcriptional profiling in experimental visceral leishmaniasis reveals a broad splenic inflammatory environment that conditions macrophages toward a disease-promoting phenotype. PLoS Pathog. 2017;13:e1006165.","journal-title":"PLoS Pathog."},{"key":"4165_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.micpath.2004.11.002","volume":"38","author":"ME Wilson","year":"2005","unstructured":"Wilson ME, Jeronimo SMB, Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog. 2005;38:147\u201360.","journal-title":"Microb Pathog."},{"key":"4165_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1084\/jem.20061141","volume":"204","author":"S Nyl\u00e9n","year":"2007","unstructured":"Nyl\u00e9n S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+ CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med. 2007;204:805\u201317.","journal-title":"J Exp Med."},{"key":"4165_CR54","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1084\/jem.20092532","volume":"207","author":"PA Darrah","year":"2010","unstructured":"Darrah PA, Hegde ST, Patel DT, Lindsay RWB, Chen L, Roederer M, et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med. 2010;207:1421\u201333.","journal-title":"J Exp Med."},{"key":"4165_CR55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1074-7613(02)00278-9","volume":"16","author":"D Jankovic","year":"2002","unstructured":"Jankovic D, Kullberg MC, Hieny S, Caspar P, Collazo CM, Sher A. In the absence of IL-12, CD4(+) T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10(\u2212\/\u2212) setting. Immunity. 2002;16:429\u201339.","journal-title":"Immunity."},{"key":"4165_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nm.1929","volume":"15","author":"J Sun","year":"2009","unstructured":"Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med. 2009;15:277\u201384.","journal-title":"Nat Med."},{"key":"4165_CR57","first-page":"293","volume":"14","author":"B Mohammadi-Ghalehbin","year":"2017","unstructured":"Mohammadi-Ghalehbin B, Hatam G, Sarkari B, Mohebali M, Zarei Z, Bohlooli S. Cytokine profile of Leishmania infantum fucose-mannose ligand in vaccinated dogs in the northwest of Iran. Iran J Immunol. 2017;14:293\u2013305.","journal-title":"Iran J Immunol"},{"key":"4165_CR58","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.molimm.2013.05.231","volume":"56","author":"J Vitoriano-Souza","year":"2013","unstructured":"Vitoriano-Souza J, das Dores Moreira N, Menezes-Souza D, Roatt BM, de Oliveira Aguiar-Soares RD, Siqueira-Mathias FA, et al. Dogs immunized with LBSap vaccine displayed high levels of IL-12 and IL-10 cytokines and CCL4, CCL5 and CXCL8 chemokines in the dermis. Mol Immunol. 2013;56:540\u20138.","journal-title":"Mol Immunol."},{"key":"4165_CR59","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.4049\/jimmunol.1003588","volume":"186","author":"NA Ansari","year":"2011","unstructured":"Ansari NA, Kumar R, Gautam S, Nyl\u00e9n S, Singh OP, Sundar S, et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol. 2011;186:3977\u201385.","journal-title":"J Immunol."},{"key":"4165_CR60","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.micinf.2005.03.010","volume":"7","author":"K Huygen","year":"2005","unstructured":"Huygen K. Plasmid DNA vaccination. Microbes Infect. 2005;7:932\u20138.","journal-title":"Microbes Infect."},{"key":"4165_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11259-007-0040-5","volume":"31","author":"MA Dea-Ayuela","year":"2007","unstructured":"Dea-Ayuela MA, Rama-I\u00f1iguez S, Alunda JM, Bolas-Fernandez F. Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for in vivo testing of antileishmanial compounds. Vet Res Commun. 2007;31:703\u201317.","journal-title":"Vet Res Commun."},{"key":"4165_CR62","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.immuni.2017.04.028","volume":"46","author":"RG Jones","year":"2017","unstructured":"Jones RG, Pearce EJ. MenTORing immunity: mTOR signaling in the development and function of tissue-resident immune cells. Immunity. 2017;46:730\u201342.","journal-title":"Immunity."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04165-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04165-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04165-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:37:45Z","timestamp":1723012665000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04165-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4165"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04165-4","relation":{},"ISSN":["1756-3305"],"issn-type":[{"type":"electronic","value":"1756-3305"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"3 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving animals were approved by the Universitat Aut\u00f2noma de Barcelona Animal Care Committee following the principles of animal protection according to the Directive 2010\/63\/UE (Protocol Number 2277).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}